- Tetra Bio-Pharma (TBP) has filed three patent applications for its novel therapeutic, ARDS-003
- The patents will provide additional protection to investors for up to 20 years from the filing date
- ARDS-003 is a novel First in Human (FIH) drug product developed to modulate acute systemic inflammation and prevent sepsis, ARDS, and organ damage
- Guy Chamberland, CEO and Chief Regulatory Officer at Tetra sat down with Sabrina Cuthbert to discuss the news
- Tetra Bio-Pharma is a leader in cannabinoid-derived drug discovery and development
- Tetra Bio-Pharma Inc. (TBP) opened trading at C$0.025
Tetra Bio-Pharma (TBP) has filed three patent applications for its novel therapeutic, ARDS-003.
Guy Chamberland, CEO and Chief Regulatory Officer at Tetra, sat down with Sabrina Cuthbert to discuss the news.
“This is a significant step in protecting our novel therapeutic, ARDS-003. It is especially significant, considering the potential use of this novel cannabinoid molecule in antiviral and immunomodulator therapies. These patents would be enforceable once granted and provide additional protection to investors for up to 20 years from the filing date.”
ARDS-003 is a novel First in Human (FIH) drug product containing the active pharmaceutical agent, Onternabez, a potent and selective full agonist of the type 2 cannabinoid receptor (CB2R). ARDS-003 is positioned to modulate acute systemic inflammation and prevent sepsis, ARDS, and organ damage.
Tetra Bio-Pharma is a leader in cannabinoid-derived drug discovery and development with an FDA and Health Canada-cleared clinical program to bring novel prescription drugs and treatments to patients and their healthcare providers.
Tetra Bio-Pharma Inc. (TBP) opened trading at C$0.025 per share.
